Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human NKAT-1/KIR2DL1/CD158a-C-His&Avi protein was developed from hek293 cells and has a target region of C-His&Avi. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
Endotoxin: |
Please contact us for more information. |
Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Human KIR2DL1 at 1 Mu g/mL (100 Mu L/well) can bind KIR2DL1 Rabbit pAb with a linear range of 1-99 ng/mL. |
Gene Symbol: |
KIR2DL1 |
Gene ID: |
3802 |
Uniprot ID: |
KI2L1_HUMAN |
Immunogen: |
Recombinant Human NKAT-1/KIR2DL1/CD158a Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (His22-Arg242) of human KIR2DL1 (Accession #NP_055033.2) fused with a 6×His, Avi tag at the C-terminus. |
Function | Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis. |
Protein Name | Killer Cell Immunoglobulin-Like Receptor 2dl1Cd158 Antigen-Like Family Member ANatural Killer-Associated Transcript 1Nkat-1P58 Natural Killer Cell Receptor Clones Cl-42/47.11P58 Nk Receptor Cl-42/47.11P58.1 Mhc Class-I-Specific Nk ReceptorCd Antigen Cd158a |
Database Links | Reactome: R-HSA-198933 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
Alternative Protein Names | Killer Cell Immunoglobulin-Like Receptor 2dl1 proteinCd158 Antigen-Like Family Member A proteinNatural Killer-Associated Transcript 1 proteinNkat-1 proteinP58 Natural Killer Cell Receptor Clones Cl-42/47.11 proteinP58 Nk Receptor Cl-42/47.11 proteinP58.1 Mhc Class-I-Specific Nk Receptor proteinCd Antigen Cd158a proteinKIR2DL1 proteinCD158A proteinNKAT1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance